{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:01:27Z","timestamp":1780106487823,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.gastrohep.2022.10.021","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T09:48:13Z","timestamp":1668160093000},"page":"671-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors"],"prefix":"10.1016","volume":"46","author":[{"given":"Mar\u00eda Roc\u00edo","family":"Davis Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-5696","authenticated-orcid":false,"given":"Mar\u00eda Pilar","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Romero-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"S\u00e1nchez-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marti-Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Tosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Suria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Ant\u00f3n Ausejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pascual Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Planelles Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"M\u00ednguez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Maia","family":"Bosca-Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2022.10.021_bib0160","series-title":"Enfermedad inflamatoria intestinal. IV Edici\u00f3n","author":"Gomoll\u00f3n","year":"2019"},{"issue":"EspecCongr2","key":"10.1016\/j.gastrohep.2022.10.021_bib0165","first-page":"107","article-title":"La presencia del alelo HLA DQA1*05 se asocia a p\u00e9rdida de respuesta a infliximab en pacientes con enfermedad inflamatoria intestinal","volume":"42","author":"Rodr\u00edguez-Alonso","year":"2019","journal-title":"Gastroenterol Hepatol"},{"issue":"EspecCongr","key":"10.1016\/j.gastrohep.2022.10.021_bib0170","first-page":"90","article-title":"La presencia del alelo HLA DQA1*05 se asocia a un mayor riesgo de p\u00e9rdida de respuesta a adalimumab en pacientes con enfermedad de Crohn","volume":"43","author":"Camps","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0175","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0180","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0185","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4067\/S0034-98872017001001319","article-title":"Factores pron\u00f3sticos en colitis ulcerosa de reciente diagn\u00f3stico. Review","volume":"145","author":"Pizarro","year":"2017","journal-title":"Rev Med Chile"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0190","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","article-title":"Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy","volume":"14","author":"Pan\u00e9s","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0195","first-page":"660","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0200","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0205","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD. Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohn's Colitis"},{"issue":"Suppl","key":"10.1016\/j.gastrohep.2022.10.021_bib0215","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0225","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Hardbord","year":"2017","journal-title":"J Crohn Colitis"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0230","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0235","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0240","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic scorefor Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0245","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","article-title":"Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-\u03b1 agents","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1399-0039.1993.tb01991.x","article-title":"HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours","volume":"41","author":"Olerup","year":"1993","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0260","first-page":"39","article-title":"Development of diagnostic technology using magnetic microparticles","volume":"21","author":"Tamatsukuri","year":"2005","journal-title":"Bio-Industry"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.gastrohep.2013.01.002","article-title":"Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa sobre el uso de f\u00e1rmacos antifactor de necrosis tumoral en la enfermedad inflamatoria intestinal (2013)","volume":"36","author":"Cabriada","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0270","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0275","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"Espec Congr","key":"10.1016\/j.gastrohep.2022.10.021_bib0280","first-page":"89","article-title":"El alelo HLA DQA1*05 no se asocia con la p\u00e9rdida de respuesta secundaria a ustekinumab en pacientes con enfermedad de Crohn","volume":"43","author":"Camps","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0285","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/genes12121934","article-title":"HLA-DQA1*05 associates with extensive ulcerative colitis at diagnosis: an observational study in children","volume":"12","author":"Nowak","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0290","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0295","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.12076","article-title":"Does co-treatment with immunossupressors improve outcome in patientswith Cronh's disease traeted with adalimumab?","volume":"36","author":"Reenaers","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0300","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn's disease patients: The SUSTAIN Study","volume":"28","author":"Chaparro","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0305","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.14167","article-title":"One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study","volume":"46","author":"Amiot","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.10.021_bib0310","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570522002679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570522002679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:47:22Z","timestamp":1759322842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570522002679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0210570522002679"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2022.10.021","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2022.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}